GERN 8-K
Geron Corp (GERN)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
___________
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices, including zip code)
(
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
On May 9, 2024, Geron Corporation (the “Company”) held its 2024 Annual Meeting of Stockholders in a virtual meeting format, pursuant to notice duly given (the “2024 Annual Meeting”). The Company’s definitive proxy statement for the 2024 Annual Meeting was filed with the United States Securities and Exchange Commission on March 27, 2024 (the “2024 Proxy Statement”). Only stockholders of record as of the close of business on March 12, 2024, the record date for the 2024 Annual Meeting, were entitled to vote at the 2024 Annual Meeting. As of March 12, 2024, 546,873,894 shares of common stock of the Company were outstanding and entitled to vote at the 2024 Annual Meeting, of which 424,014,716 shares of common stock of the Company were represented, in person or by proxy, constituting a quorum. The final results of the stockholder vote on each proposal brought before the 2024 Annual Meeting are as follows:
Name of Director Nominee |
Votes In Favor |
Votes Withheld |
Broker Non-Votes |
John F. McDonald |
277,269,957 |
5,729,979 |
141,014,780 |
John A. Scarlett, M.D. Robert J. Spiegel, M.D., FACP |
275,707,115 243,088,760 |
7,292,821 39,911,176 |
141,014,780 141,014,780 |
Votes For |
Votes Against |
Abstentions |
Broker Non-Votes |
272,059,071 |
8,999,145 |
1,941,720 |
141,014,780 |
Votes For |
Votes Against |
Abstentions |
Broker Non-Votes |
420,096,104 |
3,227,292 |
691,320 |
N/A |
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. |
Description |
104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
GERON CORPORATION
Date: |
May 13, 2024 |
|
By: |
/s/ Scott A. Samuels |
|
|
|
Name: |
Scott A. Samuels |
|
|
|
Title: |
Executive Vice President, |
|
|
|
|
Chief Legal Officer and |
|
|
|
|
Secretary |